About: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Rituximab improves the outcome of patients with non-Hodgkin lymphoma, but does not completely eradicate residual B-cell populations in the microenvironment of the bone marrow and lymph nodes. Adhesion to stromal cells can protect B-cells from apoptosis induced by chemotherapy drugs [(cell adhesion-mediated drug resistance (CAM-DR)]. A similar mechanism of resistance to rituximab has not, to our knowledge, been described. We tested the hypothesis that the microenvironment protects malignant B-cells from rituximab-induced apoptosis, and that blocking these interactions with natalizumab, an antibody targeting VLA-4 (integrin alfa-4-beta-1/CD49d), can overcome this protection. VLA-4 is an adhesion molecule constitutively expressed on malignant B-cells and is important for pro-survival signalling in the bone marrow and lymph node microenvironment.
  • Rituximab improves the outcome of patients with non-Hodgkin lymphoma, but does not completely eradicate residual B-cell populations in the microenvironment of the bone marrow and lymph nodes. Adhesion to stromal cells can protect B-cells from apoptosis induced by chemotherapy drugs [(cell adhesion-mediated drug resistance (CAM-DR)]. A similar mechanism of resistance to rituximab has not, to our knowledge, been described. We tested the hypothesis that the microenvironment protects malignant B-cells from rituximab-induced apoptosis, and that blocking these interactions with natalizumab, an antibody targeting VLA-4 (integrin alfa-4-beta-1/CD49d), can overcome this protection. VLA-4 is an adhesion molecule constitutively expressed on malignant B-cells and is important for pro-survival signalling in the bone marrow and lymph node microenvironment. (en)
Title
  • Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance
  • Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance (en)
skos:prefLabel
  • Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance
  • Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance (en)
skos:notation
  • RIV/00216224:14740/11:00057005!RIV12-MZ0-14740___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(NT11218), V
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 188608
http://linked.open...ai/riv/idVysledku
  • RIV/00216224:14740/11:00057005
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • lymphoma; stromal cells; cell adhesion-mediated drug resistance; rituximab; natalizumab (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [E4E0B0444A9F]
http://linked.open...i/riv/nazevZdroje
  • British Journal of Haematology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 155
http://linked.open...iv/tvurceVysledku
  • Ansell, Stephen
  • Church, Amy
  • Jelínek, Diane
  • Kay, Neil
  • Mráz, Marek
  • Novák, Anne
  • Nowakowski, Grzegorz
  • Pospíšilová, Šárka
  • Witzig, Thomas
  • Wu, Xiaosheng
  • Zent, Clive
http://linked.open...ain/vavai/riv/wos
  • 000294919700005
issn
  • 0007-1048
number of pages
http://bibframe.org/vocab/doi
  • 10.1111/j.1365-2141.2011.08794.x
http://localhost/t...ganizacniJednotka
  • 14740
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software